Reckitt Benckiser Pharmaceuticals, Inc., et al. v. Teva, Inc., et al., C.A. Nos. 14-1451 – RGA; 14-1573 – RGA; 14-1574 - RGA, June 29, 2016.
Sleet, J. Claim construction opinion issues regarding eleven terms from five patents. A Markman hearing took place on March 31, 2016.
The disputed technology relates to Suboxone® sublingual film. The following terms were considered:
- “said [polymer] matrix having a substantially uniform distribution of [said/said pharmaceutical/at least one] active"
- "to maintain said uniform distribution of said [pharmaceutical/at least one] active by locking-in or substantially preventing migration of said [pharmaceutical/at least one] active"
- "film having a substantially uniform distribution of said at least one active component"
- “wherein said drying apparatus uses air currents”
- "a taste-masking agent coated or intimately associated with said particulate [active]"
- "said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix"
- “dried without [the] loss of substantial uniformity”
- "wherein said local pH is from about 3 to about 3.5"
- "at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer; wherein: the water-soluble polymer component comprises greater than 75% polyethylene oxide and up to 25% hydrophilic cellulosic polymer."
- "at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer; wherein: the water-soluble polymer component comprises the hydrophilic cellulosic polymer in a ratio of up to about 4:1 with the polyethylene oxide."